# ImmunoGenix: Next-Gen Recombinant Immunoglobulin Therapy
> Discover how ImmunoGenix is revolutionizing blood immunity with recombinant SCIG therapy to treat PID and autoimmune disorders without plasma dependency.

Tags: biotech-pitch-deck, healthcare-innovation, immunoglobulin-therapy, recombinant-technology, medical-startup, pharma-investment
## ImmunoGenix: Next-Gen Blood Immunity
* Introduction to Recombinant Immunoglobulin Therapy as the future of healthcare.

## The Problem: Fragility of Blood Defense
* Current treatments for Primary Immunodeficiency Diseases (PID) rely on plasma-derived IVIG.
* Key issues: Supply shortages, high costs, and biological side effects.

## Current Market Pain Points
* **Patient Load:** PID affects 1 in 10,000–50,000 people.
* **Cost:** Annual treatments exceed $50,000 per patient.
* **Supply Risk:** 73% of the market depends on limited plasma donations.
* **Demand:** Growing at a 9.3% CAGR.

## The Solution: Recombinant IgG Therapy
* Proprietary recombinant SCIG (Subcutaneous Immunoglobulin) technology.
* Eliminates plasma dependency and reduces dosing frequency by 50%.

## Market Opportunity (2026-2034)
* Global market projected to reach **$28.7 Billion** by 2034 with a 7.2% CAGR.
* SCIG delivery segment is growing at 9.1%.

## Market Segmentation
* IgG antibodies represent 69.4% of the market.
* Integration of IgA synergy for holistic immune defense.

## Business Model
* **Pricing:** $40K/patient/year (20% below market average).
* **Channels:** 51.6% hospital dominance and direct B2B partnerships.
* **Margins:** 60%+ through scalable recombinant production.

## Go-to-Market Strategy
* **Phase 1:** US & EU markets via Key Opinion Leaders.
* **Phase 2:** Expansion into Asia-Pacific.
* **Digital:** Leveraging online pharmacy channels (10.4% CAGR).

## Financial Projections
* Target: **$800M Revenue** by Year 5.
* 35% EBITDA margin with break-even in Year 2.

## Investment Ask
* **$20M Series A** funding requested for Phase 2 trials and global launch.
* Projected 10x ROI by 2030.
---
This presentation was created with [Bobr AI](https://bobr.ai) — an AI presentation generator.